ArticleThe New England journal of medicine2023
Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin.
Article in The New England journal of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence.Blood cancer journal · 2026Pooled it
- Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL.Blood neoplasia · 2026Article
- A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.Blood cancer discovery · 2026Article
- Current treatment algorithm: diffuse large B cell lymphoma.Blood cancer journal · 2026Review
- Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.BMC medicine · 2026Article
- Establishment and characterization of a CCND1-rearranged non-mantle cell lymphoma cell line and patient-derived xenograft model.Leukemia · 2026Article
- A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphoma.bioRxiv : the preprint server for biology · 2026Article
- Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration.Blood advances · 2025Article
- Double-Hit Lymphoma: Is Lenalidomide Just Right.Blood advances · 2025Article
- Nivolumab in combination with R-CHOP for treatment-naïve diffuse large B-cell lymphoma: an evaluation of safety and efficacy.Blood advances · 2025Article
- Recent advances in understanding and management of intravascular large B-cell lymphoma.Japanese journal of clinical oncology · 2025Review
- B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements.Blood cancer discovery · 2025Article
- A Model of Intratumor and Interpatient Heterogeneity Explains Clinical Trials of Curative Combination Therapy for Lymphoma.Blood cancer discovery · 2025Article
- Polatuzumab Vedotin, zanubrutinib and rituximab (Pola-ZR) achieved rapid and deep response in untreated frail and elderly DLBCL.Annals of hematology · 2025Observational
- Article
- Review
- Evolving molecular classification of aggressive B-cell lymphoma.Histopathology · 2025Review
- Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs.British journal of haematology · 2024Review
- Heterogeneous Surface CD79b Expression in Aggressive B-Cell Lymphomas Assessed by Flow Cytometry on Lymph Node Biopsies.Cancers · 2024Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
37611128What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.